Antiretrovirals for Human Immunodeficiency Virus Treatment and Prevention in Pregnancy
- PMID: 36822704
- DOI: 10.1016/j.ogc.2022.10.013
Antiretrovirals for Human Immunodeficiency Virus Treatment and Prevention in Pregnancy
Abstract
Safe and effective antiretroviral medications are needed during pregnancy to reduce maternal morbidity and mortality associated with untreated human immunodeficiency virus (HIV) infection and to prevent viral transmission to the infant. Pharmacokinetic studies have helped inform the appropriate dosing of antiretroviral medications during pregnancy. However, data from these studies consistently become available years after initial regulatory approvals in nonpregnant adults. In this article, the authors provide an overview of considerations in use of antiretroviral medications in pregnant people with or at risk for HIV, pharmacokinetic studies that helped support recommended options, and therapies either under active investigation or in need of prospective study.
Keywords: Antiretroviral therapy; HIV; Obstetric care; Pharmacokinetics; Preexposure prophylaxis; Pregnant.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure K.M. Brooks has received consulting fees from ViiV Healthcare. K.K. Scarsi receives grant support paid to her institution from Organon, Netherlands, LLC. M. Mirochnick receives grant support paid to his institution from Gilead Sciences, United States, ViiV Healthcare and Merck; serves on 2 DSMBs for AstraZeneca; and is a consultant for Merck.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical